Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Update

Kailera Therapeutics, Inc. (NASDAQ:KLRA) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 1,954,558 shares, a growth of ? from the April 15th total of 0 shares. Based on an average trading volume of 1,694,308 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.6% of the company’s stock are sold short.

Kailera Therapeutics Stock Down 2.1%

Shares of Kailera Therapeutics stock traded down $0.46 during trading on Friday, reaching $21.04. The company’s stock had a trading volume of 482,218 shares, compared to its average volume of 796,741. Kailera Therapeutics has a fifty-two week low of $20.75 and a fifty-two week high of $28.23.

Insider Buying and Selling

In other news, major shareholder Rtw Investments, Lp purchased 500,000 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was bought at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the completion of the purchase, the insider directly owned 10,776,820 shares of the company’s stock, valued at $172,429,120. The trade was a 4.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Andrew T. Kaplan purchased 8,398,438 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was purchased at an average price of $16.00 per share, with a total value of $134,375,008.00. Following the purchase, the director directly owned 26,255,581 shares of the company’s stock, valued at $420,089,296. The trade was a 47.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 10,460,938 shares of company stock worth $167,375,008 over the last 90 days.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. William Blair assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating for the company. TD Cowen assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $57.00 price objective for the company. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday. Leerink Partners assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $42.75.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.